Advertisement

The Charles Bonnet Syndrome: a Systematic Review of Diagnostic Criteria

  • Ali G. HamedaniEmail author
  • Victoria S. Pelak
Neurologic Ophthalmology and Otology (R Shin and D Gold, Section Editors)
  • 327 Downloads
Part of the following topical collections:
  1. Topical Collection on Neurologic Ophthalmology and Otology

Abstract

Purpose

To perform a systematic review of diagnostic criteria for the Charles Bonnet syndrome (CBS).

Recent findings

Across 33 studies that specified diagnostic criteria for CBS, hallucinations and vision loss were a common requirement, but there was considerable heterogeneity regarding hallucination properties (i.e., formed vs. unformed) and the severity of vision loss. The exclusion of confounding neuropsychiatric disorders was also common, but specific disorders and their method of ascertainment were variable.

Summary

There is considerable diagnostic heterogeneity for CBS in the literature. These differences have important implications for the results of observational and interventional studies of CBS and highlight the need for unified diagnostic criteria.

Keywords

Charles Bonnet syndrome Release hallucinations Visual hallucinations Vision loss Diagnostic criteria Systematic review 

Notes

Compliance with Ethical Standards

Conflict of Interest

Ali G. Hamedani declares no potential conflicts of interest. Victoria S. Pelak reports royalties from Up-to-Date, Inc. and Elsevier.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Hedges TR. Charles Bonnet, his life, and his syndrome. Surv Ophthalmol. 2007;52(1):111–4.  https://doi.org/10.1016/j.survophthal.2006.10.007.PubMedCrossRefGoogle Scholar
  2. 2.
    de Morsier G. The Charles Bonnet syndrome: visual hallucinations in the aged without mental deficiency. Ann Med Psychol (Paris). 1967;2(5):678–702.Google Scholar
  3. 3.
    Cogan DG. Visual hallucinations as release phenomena. Albrecht Von Graefes Arch Klin Exp Ophthalmol Albrecht Von Graefes Arch Clin Exp Ophthalmol. 1973;188(2):139–50.CrossRefGoogle Scholar
  4. 4.
    Burke W. The neural basis of Charles Bonnet hallucinations: a hypothesis. J Neurol Neurosurg Psychiatry. 2002;73(5):535–41.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Schultz G, Melzack R. The Charles Bonnet syndrome: “phantom visual images”. Perception. 1991;20(6):809–25.  https://doi.org/10.1068/p200809.PubMedCrossRefGoogle Scholar
  6. 6.
    Menon GJ, Rahman I, Menon SJ, Dutton GN. Complex visual hallucinations in the visually impaired: the Charles Bonnet Syndrome. Surv Ophthalmol. 2003;48(1):58–72.PubMedCrossRefGoogle Scholar
  7. 7.
    Levine AM. Visual hallucinations and cataracts. Ophthalmic Surg. 1980;11(2):95–8.PubMedGoogle Scholar
  8. 8.
    Crumbliss KE, Taussig MJ, Jay WM. Vision rehabilitation and Charles Bonnet Syndrome. Semin Ophthalmol. 2008;23(2):121–6.  https://doi.org/10.1080/08820530801888170.PubMedCrossRefGoogle Scholar
  9. 9.
    Ukai S, Yamamoto M, Tanaka M, Takeda M. Treatment of typical Charles bonnet syndrome with donepezil. Int Clin Psychopharmacol. 2004;19(6):355–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Bergman Y, Barak Y. Escitalopram for antipsychotic nonresponsive visual hallucinosis: eight patients suffering from Charles Bonnet syndrome. Int Psychogeriatr. 2013;25(9):1433–6.  https://doi.org/10.1017/S1041610213000719.PubMedCrossRefGoogle Scholar
  11. 11.
    Hori H, Terao T, Shiraishi Y, Nakamura J. Treatment of Charles bonnet syndrome with valproate. Int Clin Psychopharmacol. 2000;15(2):117–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Lepore FE. Spontaneous visual phenomena with visual loss: 104 patients with lesions of retinal and neural afferent pathways. Neurology. 1990;40(3 Pt 1):444–7.PubMedCrossRefGoogle Scholar
  13. 13.
    McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.  https://doi.org/10.1212/WNL.0000000000004058.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    • Kosman KA, Silbersweig DA. Pseudo-Charles Bonnet syndrome with a frontal tumor: visual hallucinations, the brain, and the two-hit hypothesis. J Neuropsychiatr Clin Neurosci. 2018;30(1):84–6.  https://doi.org/10.1176/appi.neuropsych.17040076This is a case report of visual hallucinations in a 52 year-old woman with vision loss due to severe bilateral optic atrophy from a large (> 6 cm) planum sphenoidale meningioma. The patient's hallucinations resolved after resection of her meningioma, despite persistence of her vison loss. The authors discuss the hypothesis that a “second hit” besides vision loss—in this case, frontal lobe dysfunction due to mass effect and vasogenic edema from her meningioma—is required to cause release hallucinations.CrossRefGoogle Scholar
  15. 15.
    Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9W64.CrossRefGoogle Scholar
  16. 16.
    Abbott EJ, Connor GB, Artes PH, Abadi RV. Visual loss and visual hallucinations in patients with age-related macular degeneration (Charles Bonnet syndrome). Invest Ophthalmol Vis Sci. 2007;48(3):1416–23.  https://doi.org/10.1167/iovs.06-0942.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen C-C, Liu H-C. Low-dose aripiprazole resolved complex hallucinations in the left visual field after right occipital infarction (Charles Bonnet syndrome). Psychogeriatr Off J Jpn Psychogeriatr Soc. 2011;11(2):116–8.  https://doi.org/10.1111/j.1479-8301.2010.00353.x.CrossRefGoogle Scholar
  18. 18.
    Cox TM, Ffytche DH. Negative outcome Charles Bonnet syndrome. Br J Ophthalmol. 2014;98(9):1236–9.  https://doi.org/10.1136/bjophthalmol-2014-304920.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Eagan SM, Williams JA. The formed visual hallucinations associated with vision loss. Optom St Louis Mo. 2000;71(8):519–27.Google Scholar
  20. 20.
    Elflein HM, Rudy M, Lorenz K, Ponto KA, Scheurich A, Pitz S. Charles Bonnet’s syndrome: not only a condition of the elderly. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2016;254(8):1637–42.  https://doi.org/10.1007/s00417-016-3387-x.CrossRefGoogle Scholar
  21. 21.
    • ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 Feb 1 - . Identifier NCT03148249, A Trial of Patients With a Charles Bonnet Syndrome (CBS).https://clinicaltrials.gov/ct2/show/NCT03148249. Accessed April 3, 2019. This is the only clinical trial for Charles Bonnet syndrome registered on clinicaltrials.gov. Because it is a clinical trial, its inclusion and exclusion criteria form some of the strictest and most detailed diagnostic criteria (including a visual acuity cutoff, which few other studies have) for Charles Bonnet syndrome in the literature. The trial reportedly randomized patients with Charles Bonnet syndrome to consultation and treatment with a psychiatrist, and the primary outcome was quality of life. However, while it is listed as having been conducted between 2014 and 2017, its results have not been published to our knowledge.
  22. 22.
    Gilmour G, Schreiber C, Ewing C. An examination of the relationship between low vision and Charles Bonnet syndrome. Can J Ophthalmol J Can Ophtalmol. 2009;44(1):49–52.  https://doi.org/10.3129/i08-169.CrossRefGoogle Scholar
  23. 23.
    Gold K, Rabins PV. Isolated visual hallucinations and the Charles Bonnet syndrome: a review of the literature and presentation of six cases. Compr Psychiatry. 1989;30(1):90–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Holroyd S, Rabins PV, Finkelstein D, Nicholson MC, Chase GA, Wisniewski SC. Visual hallucinations in patients with macular degeneration. Am J Psychiatry. 1992;149(12):1701–6.  https://doi.org/10.1176/ajp.149.12.1701.PubMedCrossRefGoogle Scholar
  25. 25.
    Hou Y, Zhang Y. The prevalence and clinical characteristics of Charles Bonnet syndrome in Chinese patients. Gen Hosp Psychiatry. 2012;34(5):566–70.  https://doi.org/10.1016/j.genhosppsych.2012.05.007.PubMedCrossRefGoogle Scholar
  26. 26.
    Jackson ML, Drohan B, Agrawal K, Rhee DJ. Charles Bonnet syndrome and glaucoma. Ophthalmology. 2011;118(5):1005–5.e2.  https://doi.org/10.1016/j.ophtha.2011.01.007.PubMedCrossRefGoogle Scholar
  27. 27.
    Khan JC, Shahid H, Thurlby DA, Yates JRW, Moore AT. Charles Bonnet syndrome in age-related macular degeneration: the nature and frequency of images in subjects with end-stage disease. Ophthalmic Epidemiol. 2008;15(3):202–8.  https://doi.org/10.1080/09286580801939320.PubMedCrossRefGoogle Scholar
  28. 28.
    Leandro JE, Beato J, Pedrosa AC, Pinheiro-Costa J, Falcão M, Falcão-Reis F, et al. The Charles Bonnet syndrome in patients with neovascular age-related macular degeneration: association with proton pump inhibitors. Invest Ophthalmol Vis Sci. 2017;58(10):4138–42.  https://doi.org/10.1167/iovs.16-21270.CrossRefGoogle Scholar
  29. 29.
    Madill SA, Lascaratos G, Arden GB, Ffytche DH. Perceived color of hallucinations in the Charles Bonnet syndrome is related to residual color contrast sensitivity. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2009;29(3):192–6.  https://doi.org/10.1097/WNO.0b013e3181b1b2bf.CrossRefGoogle Scholar
  30. 30.
    Miyaoka T, Furuya M, Kristian L, Wake R, Kawakami K, Nagahama M, et al. Yi-gan san for treatment of charles bonnet syndrome (visual hallucination due to vision loss): an open-label study. Clin Neuropharmacol. 2011;34(1):24–7.  https://doi.org/10.1097/WNF.0b013e318206785a.PubMedCrossRefGoogle Scholar
  31. 31.
    Nalcaci S, İlim O, Oztas Z, Akkin C, Acarer A, Afrashi F, et al. The prevalence and characteristics of Charles Bonnet syndrome in Turkish patients with retinal disease. Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd. 2016;236(1):48–52.  https://doi.org/10.1159/000446295.PubMedCrossRefGoogle Scholar
  32. 32.
    Nesher R, Nesher G, Epstein E, Assia E. Charles Bonnet syndrome in glaucoma patients with low vision. J Glaucoma. 2001;10(5):396–400.PubMedCrossRefGoogle Scholar
  33. 33.
    O’Hare F, Bentley SA, Wu Z, Guymer RH, Luu CD, Ayton LN. Charles Bonnet syndrome in advanced retinitis pigmentosa. Ophthalmology. 2015;122(9):1951–3.  https://doi.org/10.1016/j.ophtha.2015.03.006.PubMedCrossRefGoogle Scholar
  34. 34.
    Olbrich HM, Engelmeier MP, Pauleikhoff D, Waubke T. Visual hallucinations in ophthalmology. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1987;225(3):217–20.CrossRefGoogle Scholar
  35. 35.
    Pliskin NH, Kiolbasa TA, Towle VL, Pankow L, Ernest JT, Noronha A, et al. Charles Bonnet syndrome: an early marker for dementia? J Am Geriatr Soc. 1996;44(9):1055–61.PubMedCrossRefGoogle Scholar
  36. 36.
    • Russell G, Harper R, Allen H, Baldwin R, Burns A. Cognitive impairment and Charles Bonnet syndrome: a prospective study. Int J Geriatr Psychiatry. 2018;33(1):39–46.  https://doi.org/10.1002/gps.4665 This is a small prospective cohort study of adults attending a low vision clinic. The authors found that 2 of 12 patients with Charles Bonnet syndrome developed dementia during the course of follow-up period, whereas none of 10 visually impaired adults without hallucinations developed dementia. The authors conclude that Charles Bonnet syndrome is not universally benign, and others have gone further to argue that it may be a forme fruste of Lewy body disease.PubMedCrossRefGoogle Scholar
  37. 37.
    Santhouse AM, Howard RJ, Ffytche DH. Visual hallucinatory syndromes and the anatomy of the visual brain. Brain J Neurol. 2000;123(Pt 10):2055–64.CrossRefGoogle Scholar
  38. 38.
    Shiraishi Y, Terao T, Ibi K, Nakamura J, Tawara A. The rarity of Charles bonnet syndrome. J Psychiatr Res. 2004;38(2):207–13.PubMedCrossRefGoogle Scholar
  39. 39.
    Singh A, Sørensen TL. Charles bonnet syndrome improves when treatment is effective in age-related macular degeneration. Br J Ophthalmol. 2011;95(2):291–2.  https://doi.org/10.1136/bjo.2010.179465.PubMedCrossRefGoogle Scholar
  40. 40.
    Singh A, Sørensen TL. The prevalence and clinical characteristics of Charles Bonnet syndrome in Danish patients with neovascular age-related macular degeneration. Acta Ophthalmol. 2012;90(5):476–80.  https://doi.org/10.1111/j.1755-3768.2010.02051.x.PubMedCrossRefGoogle Scholar
  41. 41.
    Tan CSH, Lim VSY, Ho DYM, Yeo E, Ng BY, Au Eong KG. Charles Bonnet syndrome in Asian patients in a tertiary ophthalmic centre. Br J Ophthalmol. 2004;88(10):1325–9.  https://doi.org/10.1136/bjo.2004.041947.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Teunisse RJ, Cruysberg JR, Hoefnagels WH, Verbeek AL, Zitman FG. Visual hallucinations in psychologically normal people: Charles Bonnet’s syndrome. Lancet Lond Engl. 1996;347(9004):794–7.CrossRefGoogle Scholar
  43. 43.
    Teunisse RJ, Cruysberg JR, Verbeek A, Zitman FG. The Charles Bonnet syndrome: a large prospective study in The Netherlands. A study of the prevalence of the Charles Bonnet syndrome and associated factors in 500 patients attending the University Department of Ophthalmology at Nijmegen. Br J Psychiatry J Ment Sci. 1995;166(2):254–7.CrossRefGoogle Scholar
  44. 44.
    Teunisse RJ, Zitman FG, Raes DC. Clinical evaluation of 14 patients with the Charles Bonnet syndrome (isolated visual hallucinations). Compr Psychiatry. 1994;35(1):70–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Vale TC, Fernandes LC, Caramelli P. Charles Bonnet syndrome: characteristics of its visual hallucinations and differential diagnosis. Arq Neuropsiquiatr. 2014;72(5):333–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Vukicevic M, Fitzmaurice K. Butterflies and black lacy patterns: the prevalence and characteristics of Charles Bonnet hallucinations in an Australian population. Clin Exp Ophthalmol. 2008;36(7):659–65.  https://doi.org/10.1111/j.1442-9071.2008.01814.x.PubMedCrossRefGoogle Scholar
  47. 47.
    Zhang H, Liu Z-L, Sun P, Gu F. Incidence of Charles Bonnet syndrome after intravitreal bevacizumab injection in neovascular age-related macular degeneration. Acta Ophthalmol. 2012;90(8):e647–8.  https://doi.org/10.1111/j.1755-3768.2012.02421.x.PubMedCrossRefGoogle Scholar
  48. 48.
    Hanyu H, Takasaki A, Sato T, Akai T, Iwamoto T. Is Charles Bonnet syndrome an early stage of dementia with Lewy bodies? J Am Geriatr Soc. 2008;56(9):1763–4.  https://doi.org/10.1111/j.1532-5415.2008.01814.x.PubMedCrossRefGoogle Scholar
  49. 49.
    Lapid MI, Burton MC, Chang MT, Rummans TA, Cha SS, Leavitt JA, et al. Clinical phenomenology and mortality in Charles bonnet syndrome. J Geriatr Psychiatry Neurol. 2013;26(1):3–9.  https://doi.org/10.1177/0891988712473800.PubMedCrossRefGoogle Scholar
  50. 50.
    Issa BA, Yussuf AD. Charles bonnet syndrome, management with simple behavioral technique. J Neurosci Rural Pract. 2013;4(1):63–5.  https://doi.org/10.4103/0976-3147.105618.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Bhatia MS, Srivastava S, Jhanjee A. Charles Bonnet syndrome responding to amisulpride. J Neuropsychiatr Clin Neurosci. 2012;24(3):E40.  https://doi.org/10.1176/appi.neuropsych.11080178.CrossRefGoogle Scholar
  52. 52.
    Coletti Moja M, Milano E, Gasverde S, Gianelli M, Giordana MT. Olanzapine therapy in hallucinatory visions related to Bonnet syndrome. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2005;26(3):168–70.  https://doi.org/10.1007/s10072-005-0455-0.CrossRefGoogle Scholar
  53. 53.
    Alamri SH. A low dose of risperidone resolved Charles Bonnet syndrome after an unsuccessful trial of quetiapine: a case report. Neuropsychiatr Dis Treat. 2018;14:809–11.  https://doi.org/10.2147/NDT.S161124.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Boren RA, Boren CB. Charles Bonnet syndrome treated with pimavanserin. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2019:1.  https://doi.org/10.1097/WNO.0000000000000800.
  55. 55.
    Barnes JJ. The Charles Bonnet syndrome: symptomatic relief with atypical neuroleptics: a case series. Int J Psychiatry Clin Pract. 2001;5(2):141–4.  https://doi.org/10.1080/136515001300374894.PubMedCrossRefGoogle Scholar
  56. 56.
    Hanoglu L, Yildiz S, Polat B, Demirci S, Tavli AM, Yilmaz N, et al. Therapeutic effects of rivastigmine and alfa-lipoic acid combination in the Charles Bonnet syndrome: electroencephalography correlates. Curr Clin Pharmacol. 2016;11(4):270–3.PubMedCrossRefGoogle Scholar
  57. 57.
    Takaya M, Matsusaka K, Yanagida M, Kimura R, Matsunaga H. The effects of memantine on a patient having preclinical dementia with Lewy bodies. Gen Hosp Psychiatry. 2013;35(3):327.e1–3.  https://doi.org/10.1016/j.genhosppsych.2012.06.017.CrossRefGoogle Scholar
  58. 58.
    Segers K. Charles Bonnet syndrome disappearing with carbamazepine and valproic acid but not with levetiracetam. Acta Neurol Belg. 2009;109(1):42–3.PubMedGoogle Scholar
  59. 59.
    Finucane TE. Neurontin for Charles Bonnet syndrome. J Am Geriatr Soc. 2006;54(9):1478.  https://doi.org/10.1111/j.1532-5415.2006.00877.x.PubMedCrossRefGoogle Scholar
  60. 60.
    Paulig M, Mentrup H. Charles Bonnet’s syndrome: complete remission of complex visual hallucinations treated by gabapentin. J Neurol Neurosurg Psychiatry. 2001;70(6):813–4.  https://doi.org/10.1136/jnnp.70.6.813.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Grüter T, Ayzenberg I, Gold R, Börnke C. Charles Bonnet syndrome successfully treated with levetiracetam. J Neurol. 2016;263(9):1872–5.  https://doi.org/10.1007/s00415-016-8240-y.PubMedCrossRefGoogle Scholar
  62. 62.
    Sawant NS, Bokdawala RA. Pregabalin in the treatment of Charles Bonnet syndrome. JPMA J Pak Med Assoc. 2013;63(4):530–1.PubMedGoogle Scholar
  63. 63.
    Siddiqui Z, Ramaswmay S, Petty F. Mirtazapine for Charles Bonnet syndrome. Can J Psychiatr Rev Can Psychiatr. 2004;49(11):787–8.CrossRefGoogle Scholar
  64. 64.
    Lang UE, Stogowski D, Schulze D, Domula M, Schmidt E, Gallinat J, et al. Charles bonnet syndrome: successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors. J Psychopharmacol Oxf Engl. 2007;21(5):553–5.  https://doi.org/10.1177/0269881106075275.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019
corrected publication 2019

Authors and Affiliations

  1. 1.Department of Neurology, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Departments of Neurology and Ophthalmology, The Rocky Mountain Lions Eye InstituteUniversity of Colorado School of MedicineAuroraUSA

Personalised recommendations